Key Points
-
Sepsis is a systemic inflammatory response to severe infections, which eventually leads to tissue necrosis, multi-organ failure and death. In addition to its effects on the immune system, sepsis affects other biological systems such as the coagulation system and the autonomic nervous system. Through their amplification or suppression during sepsis, inflammatory mechanisms that are normally protective for the host can become instruments of harm.
-
An overwhelming activation of the host pathogen-recognition system (in particular of Toll-like receptor 4) as a result of extensive tissue damage and/or severe infection initiates an excessive pro-inflammatory response in the early phase of sepsis, which leads to a severe imbalance of various body systems.
-
The production of pro-inflammatory mediators is linked with pathophysiological mechanisms of inflammation in sepsis. The specific pleiotropic mediators that connect various pathways of the immune response can be considered 'central hubs' in the inflammatory network. These mediators include the complement anaphylatoxin C5a, macrophage migration-inhibitory factor (MIF), the pro-inflammatory mediator high-mobility group box 1 protein (HMGB1) and the cytokine interleukin-17A (IL-17A).
-
Dysregulation of the coagulation cascade in sepsis results in severe complications, such as disseminated intravascular coagulation (DIC). Excessive activation of the complement system also has an important role in the pathogenesis of sepsis. It is now evident that the complement, coagulation and fibrinolysis systems interact in a complex network through multiple bidirectional connections. In sepsis, crosstalk between complement and coagulation pathways contributes to the pathogenesis of the disease.
-
Inflammation is under the neuronal control of the autonomic nervous system, which can reflexively modulate the inflammatory response by inhibiting the production of pro-inflammatory cytokines and is therefore referred to as the 'inflammatory reflex'. The efferent arm of the inflammatory reflex, known as the cholinergic anti-inflammatory pathway, has been found to be important for suppressing cytokine production during sepsis. By contrast, the activation of adrenergic pathways in the early phase of sepsis promotes pro-inflammatory responses through direct effects on immune cells, which can synthesize neurotransmitters and their receptors.
-
The pathology of sepsis involves a complex interplay between different biological systems that results in severe dysregulation of the inflammatory network. It is important to consider that sepsis is a heterogeneous, dynamic syndrome, and that successful treatment will require various treatment options that should be adjusted to an individual patient's situation.
Abstract
Sepsis and sepsis-associated multi-organ failure are major challenges for scientists and clinicians and are a tremendous burden for health-care systems. Despite extensive basic research and clinical studies, the pathophysiology of sepsis is still poorly understood. We are now beginning to understand that sepsis is a heterogeneous, dynamic syndrome caused by imbalances in the 'inflammatory network'. In this Review, we highlight recent insights into the molecular interactions that occur during sepsis and attempt to unravel the nature of the dysregulated immune response during sepsis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
£139.00 per year
only £11.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Thomas, L. Germs. N. Engl. J. Med. 287, 553–555 (1972).
Bone, R. C. et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101, 1644–1655 (1992).
Remick, D. G. Cytokine therapeutics for the treatment of sepsis: why has nothing worked? Curr. Pharm. Des. 9, 75–82 (2003).
Hotchkiss, R. S. & Nicholson, D. W. Apoptosis and caspases regulate death and inflammation in sepsis. Nature Rev. Immunol. 6, 813–822 (2006).
Solomkin, J. S., Jenkins, M. K., Nelson, R. D., Chenoweth, D. & Simmons, R. L. Neutrophil dysfunction in sepsis. II. Evidence for the role of complement activation products in cellular deactivation. Surgery 90, 319–327 (1981).
Harrington, L. E. et al. Interleukin-17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunol. 6, 1123–1132 (2005).
Hotchkiss, R. S. et al. Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J. Immunol. 174, 5110–5118 (2005).
Hotchkiss, R. S. et al. Depletion of dendritic cells, but not macrophages, in patients with sepsis. J. Immunol. 168, 2493–2500 (2002).
Kim, K. D. et al. Adaptive immune cells temper initial innate responses. Nature Med. 13, 1248–1252 (2007).
Huber-Lang, M. et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nature Med. 12, 682–687 (2006). This study shows that thrombin can act as a C5 convertase, which indicates that there is direct crosstalk between the coagulation and complement systems.
Tracey, K. J. The inflammatory reflex. Nature 420, 853–859 (2002).
Flierl, M. A. et al. Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature 449, 721–725 (2007). This publication identifies phagocytes as a source of catecholamines, which enhance the inflammatory response.
Bianchi, M. E. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukocyte Biol. 81, 1–5 (2007).
Medzhitov, R. & Janeway, C. Jr. Innate immunity. N. Engl. J. Med. 343, 338–344 (2000).
Poltorak, A. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085–2088 (1998). In this study, TLR4 is defined as the recognition receptor for LPS.
Ohto, U., Fukase, K., Miyake, K. & Satow, Y. Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 316, 1632–1634 (2007).
Kim, H. M. et al. Crystal structure of the TLR4–MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130, 906–917 (2007).
Park, J. S. et al. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279, 7370–7377 (2004).
Hawlisch, H. et al. C5a negatively regulates Toll-like receptor-4-induced immune responses. Immunity 22, 415–426 (2005). This study describes a negative effect of C5a on TLR4-mediated responses as an important mechanism for regulating T H 1-cell polarization in response to activation of the innate and adaptive immune systems.
Zhang, X. et al. Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood 110, 228–236 (2007).
Koleva, M. et al. Induction of anaphylatoxin C5a receptors in rat hepatocytes by lipopolysaccharide in vivo: mediation by interleukin-6 from Kupffer cells. Gastroenterology 122, 697–708 (2002).
Clark, S. R. et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nature Med. 13, 463–469 (2007).
Daubeuf, B. et al. TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock. J. Immunol. 179, 6107–6114 (2007).
McMasters, K. M., Peyton, J. C., Hadjiminas, D. J. & Cheadle, W. G. Endotoxin and tumour necrosis factor do not cause mortality from caecal ligation and puncture. Cytokine 6, 530–536 (1994).
van der Poll, T. & Opal, S. M. Host–pathogen interactions in sepsis. Lancet Infect. Dis. 8, 32–43 (2008).
Ward, P. A. The dark side of C5a in sepsis. Nature Rev. Immunol. 4, 133–142 (2004).
Ritis, K. et al. A novel C5a receptor–tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J. Immunol. 177, 4794–4802 (2006).
Riedemann, N. C. et al. Regulatory role of C5a on macrophage migration inhibitory factor release from neutrophils. J. Immunol. 173, 1355–1359 (2004).
Rittirsch, D. et al. Functional roles for C5a receptors in sepsis. Nature Med. 14, 551–557 (2008). This study indicates that both C5a receptors, C5AR and C5L2, synergistically contribute to harmful events in sepsis. In contrast to previous discussions, the authors conclude that C5L2 seems to be a functional receptor rather than a decoy receptor.
Calandra, T. & Roger, T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nature Rev. Immunol. 3, 791–800 (2003).
Lubetsky, J. B. et al. The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J. Biol. Chem. 277, 24976–24982 (2002).
Shi, X. et al. CD44 is the signaling component of the macrophage migration inhibitory factor–CD74 receptor complex. Immunity 25, 595–606 (2006).
Bernhagen, J. et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365, 756–759 (1993).
Leng, L. et al. MIF signal transduction initiated by binding to CD74. J. Exp. Med. 197, 1467–1476 (2003).
Mitchell, R. A., Metz, C. N., Peng, T. & Bucala, R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J. Biol. Chem. 274, 18100–18106 (1999).
Calandra, T. et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nature Med. 6, 164–170 (2000). This study defines a crucial role for MIF in the pathogenesis of septic shock and identifies MIF as a new target for therapeutic intervention.
Al-Abed, Y. et al. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J. Biol. Chem. 280, 36541–36544 (2005).
Muller, S. et al. New EMBO members' review. The double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J. 20, 4337–4340 (2001).
Wang, H. et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248–251 (1999). This work defined, for the first time, an extracellular role for HMGB1 as a pro-inflammatory mediator in endotoxaemia and sepsis.
Lotze, M. T. & Tracey, K. J. High mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nature Rev. Immunol. 5, 331–342 (2005).
Kim, J. Y. et al. HMGB1 contributes to the development of acute lung injury after hemorrhage. Am. J. Physiol. Lung Cell. Mol. Physiol. 288, L958–L965 (2005).
Wang, H. et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nature Med. 10, 1216–1221 (2004).
Scaffidi, P., Misteli, T. & Bianchi, M. E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191–195 (2002).
Qin, S. et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J. Exp. Med. 203, 1637–1642 (2006).
Hori, O. et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270, 25752–25761 (1995).
Sha, Y., Zmijewski, J., Xu, Z. & Abraham, E. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J. Immunol. 180, 2531–2537 (2008).
Klune, J. R., Dhupar, R., Cardinal, J., Billiar, T. R. & Tsung, A. HMGB1: endogenous danger signaling. Mol. Med. 14, 476–484 (2008).
Sunden-Cullberg, J. et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit. Care Med. 33, 564–573 (2005).
Liliensiek, B. et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 113, 1641–1650 (2004).
Yang, H. et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl Acad. Sci. USA 101, 296–301 (2004).
Weaver, C. T., Hatton, R. D., Mangan, P. R. & Harrington, L. E. IL-17 family cytokines and the expanding diversity of effector T-cell lineages. Annu. Rev. Immunol. 25, 821–852 (2007).
Flierl, M. A. et al. Adverse functions of IL-17A in experimental sepsis. FASEB J. 22, 2198–2205 (2008).
Nakae, H. et al. Serum complement levels and severity of sepsis. Res. Commun. Chem. Pathol. Pharmacol. 84, 189–195 (1994).
Gerard, C. Complement C5a in the sepsis syndrome — too much of a good thing? N. Engl. J. Med. 348, 167–169 (2003).
Kildsgaard, J. et al. Cutting edge: targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock. J. Immunol. 165, 5406–5409 (2000).
Francis, K. et al. Complement C3a receptors in the pituitary gland: a novel pathway by which an innate immune molecule releases hormones involved in the control of inflammation. FASEB J. 17, 2266–2268 (2003).
Huber-Lang, M. S. et al. Complement-induced impairment of innate immunity during sepsis. J. Immunol. 169, 3223–3231 (2002).
Huber-Lang, M. et al. Role of C5a in multiorgan failure during sepsis. J. Immunol. 166, 1193–1199 (2001).
Riedemann, N. C. et al. C5a receptor and thymocyte apoptosis in sepsis. FASEB J. 16, 887–888 (2002).
Flierl, M. A. et al. The complement anaphylatoxin C5a induces apoptosis in adrenomedullary cells during experimental sepsis. PLoS ONE 3, e2560 (2008).
Laudes, I. J. et al. Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am. J. Pathol. 160, 1867–1875 (2002).
Niederbichler, A. D. et al. An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction. J. Exp. Med. 203, 53–61 (2006).
Gerard, N. P. et al. An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. J. Biol. Chem. 280, 39677–39680 (2005).
Chen, N. J. et al. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature 446, 203–207 (2007).
Huber-Lang, M. et al. Changes in the novel orphan, C5a receptor (C5L2), during experimental sepsis and sepsis in humans. J. Immunol. 174, 1104–1110 (2005).
Zeerleder, S. et al. Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis. Clin. Diagn. Lab. Immunol. 10, 529–535 (2003).
Caliezi, C. et al. C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit. Care Med. 30, 1722–1728 (2002).
Flierl, M. A. et al. Functions of the complement components C3 and C5 during sepsis. FASEB J. 27 June 2008 (doi:10.1096/fj.08-110595).
Levi, M. & Ten Cate, H. Disseminated intravascular coagulation. N. Engl. J. Med. 341, 586–592 (1999).
Abraham, E. Coagulation abnormalities in acute lung injury and sepsis. Am. J. Respir. Cell. Mol. Biol. 22, 401–404 (2000).
Esmon, C. T. The impact of the inflammatory response on coagulation. Thromb. Res. 114, 321–327 (2004).
Stouthard, J. M. et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb. Haemost. 76, 738–742 (1996).
Bevilacqua, M. P. et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin-1. Proc. Natl Acad. Sci. USA 83, 4533–4537 (1986).
Bernard, G. R. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699–709 (2001). This study showed that treatment with activated protein C significantly decreased mortality in patients with severe sepsis, but might be associated with an increased risk of bleeding.
Maugeri, N. et al. Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation. J. Thromb. Haemost. 4, 1323–1330 (2006).
Osterud, B. & Flaegstad, T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb. Haemost. 49, 5–7 (1983).
Zeerleder, S., Schroeder, V., Hack, C. E., Kohler, H. P. & Wuillemin, W. A. TAFI and PAI-1 levels in human sepsis. Thromb. Res. 118, 205–212 (2006).
Levi, M., de Jonge, E. & van der Poll, T. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann. Med. 36, 41–49 (2004).
Esmon, C. T. The protein C pathway. Chest 124, 26S–32S (2003).
Joyce, D. E., Gelbert, L., Ciaccia, A., DeHoff, B. & Grinnell, B. W. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J. Biol. Chem. 276, 11199–11203 (2001).
Riewald, M., Petrovan, R. J., Donner, A., Mueller, B. M. & Ruf, W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296, 1880–1882 (2002).
Niessen, F. et al. Dendritic cell PAR1–S1P3 signalling couples coagulation and inflammation. Nature 452, 654–658 (2008).
Kaneider, N. C. et al. 'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage. Nature Immunol. 8, 1303–1312 (2007).
Fukudome, K. & Esmon, C. T. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J. Biol. Chem. 269, 26486–26491 (1994).
Ito, T. et al. High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J. Thromb. Haemost. 5, 109–116 (2007).
Cheng, T. et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nature Med. 9, 338–342 (2003).
Kerschen, E. J. et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J. Exp. Med. 204, 2439–2448 (2007).
Krem, M. M. & Di Cera, E. Evolution of enzyme cascades from embryonic development to blood coagulation. Trends Biochem. Sci. 27, 67–74 (2002).
Ghebrehiwet, B., Silverberg, M. & Kaplan, A. P. Activation of the classical pathway of complement by Hageman factor fragment. J. Exp. Med. 153, 665–676 (1981).
Goldberger, G. et al. NH2-terminal structure and cleavage of guinea pig pro-C3, the precursor of the third complement component. J. Biol. Chem. 256, 12617–12619 (1981).
Thoman, M. L., Meuth, J. L., Morgan, E. L., Weigle, W. O. & Hugli, T. E. C3d-K, a kallikrein cleavage fragment of iC3b is a potent inhibitor of cellular proliferation. J. Immunol. 133, 2629–2633 (1984).
Campbell, W., Okada, N. & Okada, H. Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol. Rev. 180, 162–167 (2001).
Wojta, J. et al. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood 100, 517–523 (2002).
Muhlfelder, T. W. et al. C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation. J. Clin. Invest. 63, 147–150 (1979).
Krarup, A., Wallis, R., Presanis, J. S., Gal, P. & Sim, R. B. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS ONE 2, e623 (2007).
Rezende, S. M., Simmonds, R. E. & Lane, D. A. Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S–C4b binding protein complex. Blood 103, 1192–1201 (2004).
Sternberg, E. M. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nature Rev. Immunol. 6, 318–328 (2006).
Elenkov, I. J., Wilder, R. L., Chrousos, G. P. & Vizi, E. S. The sympathetic nerve — an integrative interface between two supersystems: the brain and the immune system. Pharmacol. Rev. 52, 595–638 (2000).
Bergquist, J., Tarkowski, A., Ekman, R. & Ewing, A. Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. Proc. Natl Acad. Sci. USA 91, 12912–12916 (1994).
Munford, R. S. & Tracey, K. J. Is severe sepsis a neuroendocrine disease? Mol. Med. 8, 437–442 (2002).
Wang, H. et al. Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation. Nature 421, 384–388 (2003). This work shows that the α 7 -nicotinic acetylcholine receptor is required for acetylcholine-mediated inhibition of cytokine production by macrophages, which is also known as the cholinergic anti-inflammatory pathway.
Tracey, K. J. Physiology and immunology of the cholinergic antiinflammatory pathway. J. Clin. Invest. 117, 289–296 (2007).
Huston, J. M. et al. Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J. Exp. Med. 203, 1623–1628 (2006).
Huston, J. M. et al. Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis. Crit. Care Med. 35, 2762–2768 (2007).
Annane, D. et al. Inappropriate sympathetic activation at onset of septic shock: a spectral analysis approach. Am. J. Respir. Crit. Care Med. 160, 458–465 (1999).
Bergmann, M. & Sautner, T. Immunomodulatory effects of vasoactive catecholamines. Wien. Klin. Wochenschr. 114, 752–761 (2002).
Oberbeck, R. Catecholamines: physiological immunomodulators during health and illness. Curr. Med. Chem. 13, 1979–1989 (2006).
Oberbeck, R. et al. Adrenergic modulation of survival and cellular immune functions during polymicrobial sepsis. Neuroimmunomodulation 11, 214–223 (2004).
Kradin, R., Rodberg, G., Zhao, L. H. & Leary, C. Epinephrine yields translocation of lymphocytes to the lung. Exp. Mol. Pathol. 70, 1–6 (2001).
Ackerman, K. D., Madden, K. S., Livnat, S., Felten, S. Y. & Felten, D. L. Neonatal sympathetic denervation alters the development of in vitro spleen cell proliferation and differentiation. Brain Behav. Immun. 5, 235–261 (1991).
Spengler, R. N., Allen, R. M., Remick, D. G., Strieter, R. M. & Kunkel, S. L. Stimulation of α-adrenergic receptor augments the production of macrophage-derived tumor necrosis factor. J. Immunol. 145, 1430–1434 (1990).
Freestone, P. P. et al. Growth stimulation of intestinal commensal Escherichia coli by catecholamines: a possible contributory factor in trauma-induced sepsis. Shock 18, 465–470 (2002).
Zhou, M., Das, P., Simms, H. H. & Wang, P. Gut-derived norepinephrine plays an important role in up-regulating IL-1β and IL-10. Biochim. Biophys. Acta 1740, 446–452 (2005).
Yang, S., Zhou, M., Chaudry, I. H. & Wang, P. Norepinephrine-induced hepatocellular dysfunction in early sepsis is mediated by activation of α2-adrenoceptors. Am. J. Physiol. Gastrointest. Liver Physiol. 281, G1014–G1021 (2001).
Yang, S., Koo, D. J., Zhou, M., Chaudry, I. H. & Wang, P. Gut-derived norepinephrine plays a critical role in producing hepatocellular dysfunction during early sepsis. Am. J. Physiol. Gastrointest. Liver Physiol. 279, G1274–G1281 (2000).
Zhou, M. et al. The role of Kupffer cell α2-adrenoceptors in norepinephrine-induced TNF-α production. Biochim. Biophys. Acta 1537, 49–57 (2001).
Dombrovskiy, V. Y., Martin, A. A., Sunderram, J. & Paz, H. L. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit. Care Med. 35, 1244–1250 (2007). This publication is the most recent study to describe the epidemiology of sepsis in the United States. Most importantly, the rates of hospitalization and mortality from severe sepsis increased significantly over the observation period from 1993 to 2003.
Rittirsch, D., Hoesel, L. M. & Ward, P. A. The disconnect between animal models of sepsis and human sepsis. J. Leukocyte Biol. 81, 137–143 (2007).
Levy, M. M. et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 31, 1250–1256 (2003).
Calvano, S. E. et al. A network-based analysis of systemic inflammation in humans. Nature 437, 1032–1037 (2005).
Rossaint, R. et al. Key issues in advanced bleeding care in trauma. Shock 26, 322–331 (2006).
Westfall, T. C. & Westfall, D. P. in Goodman & Gilman's The Pharmacological Basis of Therapeutics (eds Brunton, L. L., Lazo, J. S. & Parker, K. L.) 153–158 (McGraw-Hill, New York, 2006).
Acknowledgements
This work was supported by grants GM-29,507, HL-31963 and GM-61656 from the National Institutes of Health, USA, to P.A.W.
Author information
Authors and Affiliations
Corresponding author
Related links
Glossary
- Sepsis
-
A systemic response to severe infection or tissue damage, leading to a hyperactive and unbalanced network of pro-inflammatory mediators. Vascular permeability, cardiac function and metabolic balance are affected, resulting in tissue necrosis, multi-organ failure and death.
- TH17 cells
-
(T helper 17 cells). A subset of CD4+ T helper cells that produce interleukin-17 (IL-17) and that are thought to be important in inflammatory and autoimmune diseases. Their generation involves IL-23 and IL-21, as well as the transcription factors RORγt (retinoic-acid-receptor-related orphan receptor-γt) and STAT3 (signal transducer and activator of transcription 3).
- Nosocomial infections
-
These are infections that occur during treatment in a hospital or a healthcare service unit and are secondary to the patient's original condition. Nosocomial stems from the Greek word 'nosokomeion' meaning hospital ('nosos', disease; 'komeo', to take care of). This type of infection is also known as a hospital-acquired infection.
- Anaphylatoxin
-
The pro-inflammatory complement-activation fragments C3a, C4a and C5a are also known as anaphylatoxins. They mediate inflammatory responses through cell activation and induce effects such as chemotaxis and histamine release.
- Neutrophil extracellular traps
-
(NETs). A set of extracellular fibres produced by activated neutrophils to ensnare invading microorganisms. NETs enhance neutrophil killing of extracellular pathogens while minimizing damage to host cells.
- Tautomerase activity
-
The ability to catalyse the tautomerization (switching from one isomeric form to another) of D-dopachrome and L-dopachrome methyl ester into their corresponding indole derivates. This reaction was used by early life forms for synthetic pathways. Macrophage migration-inhibitory factor (MIF) has been shown to have tautomerase activity; this evolutionarily conserved catalytic function is responsible for its pro-inflammatory effects.
- Cholinergic anti-inflammatory pathway
-
This pathway fine-tunes cytokine production during inflammation in a highly regulated and reflexive manner. Interaction of acetylcholine with the α7-nicotinic acetylcholine receptor (α7nAChR) expressed by macrophages results in the suppression of pro-inflammatory cytokine production. The main component of this pathway is the vagus nerve of the parasympathetic branch of the autonomic nervous system.
- Endotoxaemia
-
This is caused by the presence of endotoxins, which are derived from Gram-negative bacteria, in the blood. It results in systemic activation of the inflammatory response, the development of shock and multi-organ failure and death. Models of endotoxaemia are used in experimental settings to induce systemic inflammation, but they do not necessarily mimic human sepsis.
- Septic cardiomyopathy
-
The decreased myocardial function that occurs during sepsis-associated multi-organ failure. Hypotheses concerning the aetiology of this decreased function include impairment of mitochondrial function, dysfunction of the β-adrenoceptor–G-protein–adenylate cyclase system, calcium-channel blockade by direct and indirect cardiodepressant factors and contractile impairment by activated leukocytes.
- Disseminated intravascular coagulation
-
(DIC). Also known as consumptive coagulopathy, this is a pathological process in which the blood begins to coagulate throughout the entire body. During this process, platelets and coagulation factors are depleted, resulting in a paradoxical situation in which there is a high risk of simultaneous fatal thrombosis and large-scale haemorrhage. DIC often occurs in critically ill patients with overwhelming infection, fulminant sepsis or malignancy.
- Thrombin
-
Thrombin (also known as activated Factor II) is the central serine protease that converts soluble fibrinogen into insoluble strands of fibrin. It also catalyses many other coagulation-related reactions.
- Tissue factor
-
A pro-coagulant factor that stimulates thrombus formation following contact with blood by accelerating the action of the coagulation factors Factor VIIa and Factor Xa. It can also be expressed on the surface of activated endothelial cells.
- Activated protein C
-
A physiological anticoagulant. The activated form degrades Factor Va and Factor VIIIa of the coagulation cascade. The protein-C pathway has anti-thrombotic activity, as well as anti-inflammatory and anti-apoptotic functions. Administration of human recombinant activated protein C for the treatment of sepsis might block dysregulated coagulation, inhibit pro-inflammatory pathways and preserve organ function.
- Thrombomodulin
-
An integral membrane protein that is expressed on the surface of endothelial cells. It functions as a co-factor in thrombin-induced activation of protein C in the anticoagulant pathway by forming complexes with thrombin. Thrombomodulin–thrombin complexes also stimulate fibrinolysis by cleaving thrombin-activatable fibrinolysis inhibitor (TAFI) into its active form.
- Catecholamines
-
Tyrosine-derived mediators that are produced mainly by the adrenal medulla and by the postganglionic fibres of the sympathetic nervous system. Recently, it has been found that immune cells are also a source of catecholamines. The most abundant catecholamines are the biogenic amines adrenaline, noradrenaline and dopamine, which function as neurotransmitters in the sympathetic branch of the autonomic nervous system through interaction with adrenergic receptors expressed by numerous cell and tissue types.
- Kupffer cells
-
The resident macrophages of the liver, which are derived from blood monocytes. They phagocytose pathogenic particles and microorganisms that have entered the liver sinusoids.
Rights and permissions
About this article
Cite this article
Rittirsch, D., Flierl, M. & Ward, P. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 8, 776–787 (2008). https://doi.org/10.1038/nri2402
Issue Date:
DOI: https://doi.org/10.1038/nri2402
This article is cited by
-
Activation of senescence in critically ill patients: mechanisms, consequences and therapeutic opportunities
Annals of Intensive Care (2024)
-
Understanding the pathophysiology of acute critical illness: translational lessons from zebrafish models
Intensive Care Medicine Experimental (2024)
-
A nomogram to predict postoperative deep vein thrombosis in patients with femoral fracture: a retrospective study
Journal of Orthopaedic Surgery and Research (2023)
-
Prognostic impact of blood urea nitrogen to albumin ratio on patients with sepsis: a retrospective cohort study
Scientific Reports (2023)
-
Neutrophil extracellular trap inhibition improves survival in neonatal mouse infectious peritonitis
Pediatric Research (2023)